Category: Jurisdictions
-
Contrasting appellate tactics show Amazon feels protected by UK ASI against InterDigital’s Munich AILI, but is scared of UPC sua sponte sanctions
There are two striking differences between Amazon’s UPC and Munich appeals of InterDigital’s anti-interim-license injunctions.
-
Tesla should learn from Amazon-InterDigital, take an Avanci 5G license: even if its long-shot UKSC appeal succeeded, it wouldn’t help
For cross-jurisdictional reasons, Tesla should give up on its UK case against Avanci and InterDigital, in which it lost the first two rounds.
-
CJEU publishes European Parliament’s suit against European Commission’s decision to withdraw SEP Regulation
The Commission “prematurely” brought the legislative procedure to an end without legitimate grounds supported by cogent evidence and arguments for doing so, the EP has alleged.
-
China’s top court grants Novo Nordisk win over key Ozempic patent
China’s Supreme People’s Court has upheld a lower court’s decision recognizing the validity of Novo Nordisk’s compound patent related to semaglutide, which is found in the company’s blockbuster drugs Ozempic, Wegovy, and Rybelsus.
-
Munich I Regional Court crashes through 300-mark, sets new record for patent infringement filings in one year
The exact number will become known in the weeks ahead, but it’s already certain to set a new record.
-
UPC threatens Amazon with initial €50M ($59M) fine, “severe consequences”, declares all UK interim licenses unenforceable, suggests EU WTO action against UK
The UPC’s Mannheim LD issued a bombshell order just before Christmas, followed by a Christmas Eve notification to the European Commission that could lead to a WTO complaint.
-
Opposition brief filed: could copyright-related case law persuade Judge Albright to lift BMW’s antisuit injunction against Munich lawsuit over U.S. patents?
Onesta has raised various arguments against BMW’s antisuit motion, some of which are potentially more compelling than others.
-
Novo Nordisk suffers another loss in efforts to extend key Ozempic patent in Brazil
Brazil’s Superior Tribunal de Justiça has issued its first-ever decision on patent term adjustment, ruling that Novo Nordisk’s request to extend its Ozempic-related patent is unconstitutional because a drugmaker’s rights to a patent term cannot override society’s rights to affordable medicine.
-
BREAKING: Within hours of Brazilian injunction, HEVC Advance lists Hisense as licensee
The Brazilian court gave Hisense only 48 hours to comply. and a preliminary injunction based on a report by a court-appointed expert has teeth.